The Canada Nation

Your Trusted news Source

Kidney Patients Call 2026 Voter Registration Campaign a Success

Kidney Patients Call 2026 Voter Registration Campaign a Success


2026 Results Fuel 2028 Goal of One Million Kidney, Heart, and Diabetic Voters

Key Motivators: Disease Screening, Organ Donor Protections, New Transplant Drugs

WASHINGTON, Nov. 20, 2026 /PRNewswire/ — The American Association of Kidney Patients (AAKP), the nation’s oldest and largest independent kidney patient advocacy organization, today announced the results and impact of its 2026 national, nonpartisan KidneyVoter™ campaign, “50 States in 50 Days.” Launched on September 14, 2026, the campaign successfully engaged and mobilized key patient and professional constituencies across all 50 states, from Maine to Washington. The 2026 campaign reached a broad sector of the electorate impacted by kidney, heart, and diabetes issues, including kidney patients, living organ donors, families, care partners, advocates, researchers, healthcare professionals, and employees of small and large companies responsible for innovations in new diagnostics, drugs, and devices. 

An estimated 90% of U.S. adults, or approximately 240 million people, have some degree of interconnected cardiovascular, kidney, or metabolic health conditions according to the American Heart Association. Kidney disease impacts more than 37 million Americans and their families. Further, interrelated cardiovascular, kidney, and metabolic diseases have impacted more than 25% of the adult population and are a leading cause of death.

On October 20, 2026, U.S. Health and Human Services Secretary Robert F. Kennedy, Jr. announced the new Kidney Care National Plan (read fact sheet), a policy framework designed to bend the curve of kidney disease occurrence, improve patient outcomes, and make America healthier. The plan advances kidney care principles and goals first outlined in President Donald J. Trump’s bipartisan 2019 Executive Order on Advancing American Kidney Health. AAKP has voiced strong support for the Kidney Care National Plan and was heavily involved in the development of the 2019 Executive Order on Advancing American Kidney Health. AAKP has also endorsed HHS’ recently announced Make America Healthy Again: Enhancing Lifestyle and Evaluating Value-based Approaches Through Evidence (MAHA ELEVATE) Model, resourced with nearly $50 million through the Centers for Medicare & Medicaid Services (CMS), to test new approaches to chronic disease prevention and management for people with Medicare.

Following the success of AAKP’s 2024 nonpartisan KidneyVoter™ campaign, which engaged more than 500,000 KidneyVoters™ and was credited by nationally recognized election data experts with establishing a new “micro-constituency” within the American electorate, AAKP expanded the program for 2026. In 2026, AAKP integrated KidneyVoter™ within its core policy education efforts, including:

  • AAKP’s Annual Public Policy Summit held at the National Press Club in Washington, D.C.;
  • All Kidney Policy is Local™, which connects patients and care partners with elected leaders in their home district offices during the Congressional summer recess; and
  • AAKP’s “50 States in 50 Days” voter registration, engagement, and mobilization campaign.

AAKP broadened its strategic messaging and social media outreach across the cardio-kidney-metabolic (CKM) syndrome spectrum to reach people living with heart disease, diabetes, and other metabolic conditions such as obesity. Building on the lessons of 2026, and in preparation for the 2028 federal election cycle, AAKP has developed new internal capacities and external alliances to engage HeartVoters™, DiabetesVoters™, CKMVoters™, CardioKidneyMetabolicVoters™, RareDiseaseVoters™, RareKidneyDiseaseVoters™, and ChronicDiseaseVoters™. AAKP estimates that by 2028 it will educate and engage more than one million KidneyVoters™ and others living with related, interconnected chronic conditions.

AAKP President Edward V. Hickey, III, a chronic kidney disease patient, stated, “AAKP’s KidneyVoter™ program continues to engage, at scale, patients, organ donors and donor families, and medical experts affected by cardio, kidney, and metabolic conditions. Our 2026 program resonated with a broad and highly diverse cross‑section of voters, with engagement levels that exceeded even our most ambitious goals. The key takeaway from Election Day 2026 is that patients see a clear connection between their elected leaders and the policies that support innovation and access to new, safe treatments that protect their lives and livelihoods. With initiatives like the expanded KidneyVoter™ program, patients and patient communities are showing that they are informed, engaged, and attentive to which leaders are championing their health outcomes. We look forward to working with policymakers in Washington, D.C. who share that commitment.” Hickey is a U.S. Marine Corps Veteran, a former senior Congressional aide, and has served in appointed roles in two presidential administrations. He currently serves on the American Board of Internal Medicine’s (ABIM) Nephrology Specialty Board and as the Chair of the AAKP Veterans Health Initiative, the largest Veteran kidney health outreach program outside of the U.S. Department of Veterans Affairs.

KidneyVoters™ use their social media networks, voices, and votes to bring Congressional and White House attention to issues that undermine America’s efforts to save more innocent lives from chronic diseases and to reduce health spending. Among the top issues motivating 2026 KidneyVoter™ engagement and registration were pending Congressional legislation related to insurance and job protections for living organ donors, the 20-year failure of the U.S. Preventive Services Task Force (USPSTF) to recommend kidney disease screening for those at high-risk, the lack of progress by the U.S. Food and Drug Administration to advance a new generation of safer organ transplant drugs, anti-competitive practices of America’s large corporate dialysis providers, utilization by payers of anti-patient and discriminatory Quality Adjusted Life Year (QALYs) measures, and negative Government Determinants of Health (GDoH) including obsolete federal regulations and Medicare reimbursement policies that stymie innovation and patient choice of new treatments.

AAKP Vice President and Chair of Policy and Global Affairs Paul T. Conway, a 49-year kidney patient and 29-year transplant recipient, stated, “The American people understand that early disease detection through screening and timely interventions with safe, FDA-approved diagnostics, drugs, and devices saves lives and reduces costs for both families and taxpayers. They are deeply empathetic toward people managing chronic diseases, like kidney disease, and understand the significant challenges they pose to a person’s ability to maintain either full-time or part-time employment. AAKP’s 2026 KidneyVoter™ program provided a platform for patients and families impacted by multiple chronic diseases to raise their voices and send a message to Congressional leaders that their patience for government inaction has a limit. We hope Congress respects the voice of patients and redoubles its efforts to provide bipartisan solutions to address the unmet needs of patients and organ donors. The electoral impact of chronic disease patients and organ donors is growing, and the time is now for Congress to demonstrate progress on behalf of all people who bear the burdens of preventable chronic illnesses.” Conway is a former Chief of Staff of the U.S. Department of Labor and past Chair of the U.S. Food and Drug Administration’s Patient Engagement Advisory Committee (PEAC). He has served on the American Board of Internal Medicine’s (ABIM) Nephrology Specialty Board and is a member of the American Diabetes Association’s Kidney Disease Workgroup.

In 2024, AAKP patient advocates led the kidney community by calling for the immediate dismissal of the U.S. Preventive Services Task Force (USPSTF) leadership, citing USPSTF’s 20-year record of incompetence and failure to issue a screening recommendation for kidney disease for the most vulnerable Americans. The USPSTF failure occurred despite USPSTF’s access to overwhelming peer-reviewed evidence of the dangers of disease progression, high mortality rates among organ failure patients, increased utilization of taxpayer-funded dialysis, and growing demand for donated organs. AAKP has expressed strong support for Health and Human Services Secretary Robert F. Kennedy, Jr.’s recent appointments to the USPSTF of specialists familiar with interrelated heart, kidney, and metabolic issues.

AAKP, alongside a broad coalition of patient organizations, transplant experts, and Congressional allies, is working to secure passage of the bipartisan Living Donor Protection Act (LDPA), S. 1552/H.R. 4582 and H.R. 4583. The legislation protects living organ donors from job and insurance discrimination based solely on their decision to donate a kidney to save another life, barriers cited most often by potential organ donors. The bipartisan bill is led by Senator Tom Cotton (R-AK) and Senator Kirsten Gillibrand (D-NY). It was voted out of the Senate HELP Committee on February 26, 2026, with full bipartisan support, the endorsement of AAKP, the united kidney community, and the American Council of Life Insurance (ACLI). In 2018, with bipartisan support from Congress and the Trump Administration, AAKP and transplant professionals worked with the U.S. Department of Labor’s (DOL) legal team and the DOL Wage and Hour Division to have DOL extend Family and Medical Leave Act (FMLA) protections for living organ donors, based on the original intent of the FMLA’s Congressional co-sponsors (click here to read the letter and click here to watch the video). Congressional passage of the LDPA in 2026 will codify the DOL’s 2018 FMLA job protections and prohibit insurers from discriminating against living donors.

Follow AAKP on social media at @kidneypatient on Facebook, @kidneypatients on X, and @kidneypatients on Instagram, and visit https://www.aakp.org for more information. AAKP patient advocates advance bipartisan kidney policy including: passage of the bipartisan law modernizing the Organ Procurement and Transplantation Network (OPTN) (2023); lifetime transplant drug coverage for kidney patients (2020); the historic Executive Order on Advancing American Kidney Health signed by President Donald Trump (2019); job protections for living organ donors under the Family Medical Leave Act (FMLA) via the U.S. Department of Labor (2018); and Congressional approval of HIV positive organ transplants for HIV positive patients (2013).

MEDIA CONTACT:
Brendan LaCivita
Director, Media Relations
[email protected]
(813) 906-7740

SOURCE American Association of Kidney Patients